Prolongation of survival time and improvement of the quality of life after treatment with irinotecan liposomal in the patient with metastatic pancreatic adenocarcinoma Case report

Article Sidebar

PDF


Published: Jul 15, 2021
DOI: https://doi.org/10.24292/01.OR.123150721
Keywords:
pancreatic cancer, chemotherapy, gemcitabine, liposomal irinotecan

Main Article Content

Wojciech Rogowski
1. Department of Clinical Oncology, Chemotherapy, Clinical Research, Provincial Specialist Hospital in Slupsk. 2. Pomeranian Academy in Slupsk
Przemysław Będkowski
1. Department of Clinical Oncology, Chemotherapy, Clinical Research, Provincial Specialist Hospital in Slupsk. 2. Department of Daily Chemotherapy, Provincial Hospital in Koszalin

Abstract

Pancreatic cancer is one of the malignant neoplasms with the worst prognosis. It is most often diagnosed at an advanced stage, which relates to unsatisfactory results of the therapy. Only about 15–20% of patients with pancreatic cancer qualify for surgery. The remaining patients are diagnosed with locally advanced disease or much more frequently in the generalized stage. Systemic treatment (chemotherapy) remains the mainstay of therapy in these patients, but both the response rate and progression-free time are unsatisfactory [1, 2].


This paper presents a case of a patient with metastatic pancreatic cancer, in whom three lines of systemic treatment were applied sequentially, which allowed to extend the survival time and improve the quality of life.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Rogowski W, Będkowski P. Prolongation of survival time and improvement of the quality of life after treatment with irinotecan liposomal in the patient with metastatic pancreatic adenocarcinoma. OncoReview [Internet]. 2021Jul.15 [cited 2024Apr.18];11(3(43):77-9. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1519
Issue
Vol 11 No 3(43) (2021)
Section
PERSONALIZED ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Vincent A, Herman J, Schulick R et al. Pancreatic cancer. Lancet. 2011; 378(9791): 607-20.
2. McGuigan A, Kelly P, Turkington RC et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846-61. http://doi.org/10.3748/wjg.v24.i43.4846.
3. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy (access: 1.03.2021).
4. Martín AM, Hidalgo M, Alvarez R et al. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer. 2018; 9(11): 1978-88. http://doi.org/10.7150/jca.23716.
5. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-703.
6. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.